The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Increased Expression of Cyclooxygenases and Peroxisome Proliferator-Activated Receptor-γ in Alzheimer's Disease Brains
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Cited by
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Moreno, S., Farioli-Vecchioli, S., & Cerù, M. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 587
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Chlorinative stress: An under appreciated mediator of neurodegeneration?
Yap, Y. W., Whiteman, M., & Cheung, N. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.06.013 · Cited by 570
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Colangelo, V., Schurr, J., Ball, M. J., Pelaez, R. P., Bazan, N. G., & Lukiw, W. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10351 · Cited by 517
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“Several investigators have detected increased levels of COX-2 mRNA and pro- tein staining in AD tissue (Ho et al. 2001; Kitamura et al. 1999; Oka and Takashima 1997; Yasojima et al. 1999a) while others have found decreased COX-2 expression, particularly in late stage AD (O’Banion et al. 1997;…”
BackgroundInfluentialContribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
Alzheimer's disease: the two-hit hypothesis
Zhu, X., Raina, A. K., Perry, G., & Smith, M. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00707-0 · Cited by 426
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor
Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424
Microglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
The role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337
Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapy
Mitchell, J. A., & Warner, T. D. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702897 · Cited by 321
Resolution of inflammation is altered in Alzheimer's disease
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.024 · Cited by 301
Elevated CSF prostaglandin E 2 levels in patients with probable AD
Montine, T. J., Sidell, K. R., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.53.7.1495 · Cited by 277
Apoptosis in Alzheimer's disease—an update
Shimohama, S. (2000) · Apoptosis · doi:10.1023/a:1009625323388 · Cited by 253
Self-citationGasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“An increased expression of PPAR γ in AD brains has been observed and it is suggested that activators may inhibit inflammatory events and be beneficial in the treatment of AD (Kitamura et al., 1999).”
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161
Heneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150
Geng, L., Zhang, T., Liu, W., & Chen, Y. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.9.1096 · Cited by 65
Wojtowicz, A. K., Szychowski, K. A., & Kajta, M. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9434-z · Cited by 62
“Keywords TBBPA PPAR-c Neurotoxicity Apoptosis Neocortex GW1929”
BackgroundPro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain
Paris, D., Townsend, K. P., Obregon, D. F., Humphrey, J., & Mullan, M. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00111-9 · Cited by 40
Song, N., Zhang, L., Chen, W., Zhu, H., Deng, W., Han, Y., Guo, J., & Qin, C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.016 · Cited by 36
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Metadata
- Authors
- Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J.-I., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P. J., & Taniguchi, T.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 1999-01
- Volume
- 254
- Issue
- 3
- Pages
- 582-586
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2065742642
- Cited by
- 207
- References
- 4
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.